Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Aug 15, 2013; 4(4): 88-91
Published online Aug 15, 2013. doi: 10.4239/wjd.v4.i4.88
Published online Aug 15, 2013. doi: 10.4239/wjd.v4.i4.88
Status of autoimmune diabetes 20-year after generation of BDC2.5-TCR transgenic non-obese diabetic mouse
Lourdes Ramirez, Abdel Rahim A Hamad, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States
Author contributions: Both authors contributed to this paper.
Supported by The NIH (1R56AI099027 and 1R01AI099027-01); and American Heart Association (10GRNT4200003)
Correspondence to: Abdel Rahim A Hamad, Assistant Professor, Department of Pathology, Johns Hopkins University School of Medicine, Ross 664G, 720 Rutland Ave, Baltimore, MD 21205, United States. ahamad@jhmi.edu
Telephone: +1-410-6143021 Fax: +1-410-6143548
Received: April 9, 2013
Revised: May 22, 2013
Accepted: June 8, 2013
Published online: August 15, 2013
Processing time: 127 Days and 13.6 Hours
Revised: May 22, 2013
Accepted: June 8, 2013
Published online: August 15, 2013
Processing time: 127 Days and 13.6 Hours
Core Tip
Core tip: Our understanding of type 1 diabetes pathogenesis has significantly improved over the last three decades. We went from not knowing very little to acquisition of significant details about the role of the immune system and different T cell subsets in the disease process. The non-obese diabetic mouse model contributed and continues to contribute to our understanding of the disease process. This article pays tributes to the major role T-cells bearing-cell-specific T-cell receptors transgenic mouse played in shaping of our understanding of the disease process. We also divulge to briefly discuss current challenges facing development of a safe immunotherapy for the disease.